What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings?

Zymeworks Inc. (NASDAQ:ZYME) – Stock analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for Zymeworks in a report released on Monday, May 11th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.29) per share for the quarter, down from their previous estimate of ($0.28). HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.13 per share. HC Wainwright also issued estimates for Zymeworks’ Q3 2026 earnings at $2.17 EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at $1.00 EPS.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company lifted their price target on shares of Zymeworks from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Monday, April 20th. Truist Financial raised Zymeworks to a “strong-buy” rating in a research note on Monday, April 27th. Stifel Nicolaus increased their price target on Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Leerink Partners raised their price target on Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Zymeworks Stock Performance

Shares of NASDAQ:ZYME opened at $23.90 on Wednesday. Zymeworks has a 52 week low of $10.93 and a 52 week high of $29.75. The company has a market capitalization of $1.75 billion, a PE ratio of -17.45 and a beta of 1.20. The company has a 50 day moving average price of $25.63 and a two-hundred day moving average price of $24.19.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share for the quarter. Zymeworks had a negative net margin of 126.92% and a negative return on equity of 37.97%. The firm had revenue of $2.41 million during the quarter.

Hedge Funds Weigh In On Zymeworks

A number of large investors have recently added to or reduced their stakes in the company. Optiver Holding B.V. acquired a new stake in shares of Zymeworks in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Zymeworks during the fourth quarter worth about $37,000. Quarry LP acquired a new position in shares of Zymeworks during the third quarter worth about $50,000. Tower Research Capital LLC TRC grew its holdings in shares of Zymeworks by 29.6% during the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after buying an additional 1,131 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Zymeworks by 25.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock valued at $96,000 after buying an additional 731 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.